EKTA.B

54

-0.55%↓

EKTA.B

54

-0.55%↓

EKTA.B

54

-0.55%↓

EKTA.B

54

-0.55%↓

EKTA.B

54

-0.55%↓

Search

Camurus AB

Closed

581 -1.44

Overview

Share price change

24h

Current

Min

581

Max

584

Key metrics

By Trading Economics

Income

24M

166M

Sales

74M

553M

P/E

Sector Avg

88.488

73.239

EPS

2.45

Profit margin

30.023

Employees

256

EBITDA

21M

190M

Market Stats

By TradingEconomics

Market Cap

38B

Previous open

582.44

Previous close

581

Camurus AB Chart

Past performance is not a reliable indicator of future results.

Related News

30 Mar 2025, 23:43 UTC

Market Talk

Gold Edges Higher, Supported by Looming U.S. Tariffs -- Market Talk

30 Mar 2025, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

30 Mar 2025, 23:41 UTC

Market Talk

Nikkei May Fall Amid Concerns About U.S. Tariffs, Borrowing Costs -- Market Talk

30 Mar 2025, 23:12 UTC

Earnings

Tsingtao Brewery 2024 Net CNY4.34B Vs. Net CNY4.27B >0168.HK

30 Mar 2025, 23:12 UTC

Earnings

Tsingtao Brewery Board Proposes Final Dividend of CNY2.20/Share >0168.HK

30 Mar 2025, 23:12 UTC

Earnings

Tsingtao Brewery 2024 Rev CNY32.14B Vs. CNY33.94B >0168.HK

30 Mar 2025, 22:30 UTC

Earnings

Great Wall Motor 2024 Net CNY12.69 Vs. Net CNY7.02B >2333.HK

30 Mar 2025, 22:30 UTC

Earnings

Great Wall Motor: Higher Overseas Vehicle Sales Among Factors Supporting Results >2333.HK

30 Mar 2025, 22:30 UTC

Earnings

Great Wall Motor 2024 Rev CNY202.20B Vs. CNY173.21B >2333.HK

30 Mar 2025, 21:44 UTC

Market Talk

Barclays Favors Core Bonds Over Equities as Tariffs Loom -- Market Talk

30 Mar 2025, 21:24 UTC

Market Talk

Early Polling Shows Labor's Support Firms Before Australia Vote -- Market Talk

30 Mar 2025, 21:23 UTC

Top News

Trump Team Weighs Broader, Higher Tariffs -- WSJ

30 Mar 2025, 16:23 UTC

Top News

Tesla's EV Credit Income Is Still Rolling In -- for Now -- Barrons.com

30 Mar 2025, 09:30 UTC

Top News

The AI Data-Center Boom Is Coming to America's Heartland -- WSJ

30 Mar 2025, 09:30 UTC

Top News

Tariffs on Screws Are Already Hitting Manufacturers -- WSJ

29 Mar 2025, 13:00 UTC

Top News

Trump's Trade War Arrives in America's Heartland -- WSJ

29 Mar 2025, 11:00 UTC

Top News

Selling Your House This Spring? You Might Need to Cut the Price -- Heard on the Street -- WSJ

29 Mar 2025, 09:30 UTC

Top News

The Auto Union Boss Who Went From Trump Foe to Tariff Cheerleader -- WSJ

29 Mar 2025, 08:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

29 Mar 2025, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

29 Mar 2025, 00:00 UTC

Top News

The Drone-Delivery Service Beating Amazon to Your Front Door -- WSJ

28 Mar 2025, 23:16 UTC

Acquisitions, Mergers, Takeovers

CoreWeave Debuts: A Big IPO in a Slow Year -- Barrons.com

28 Mar 2025, 22:21 UTC

Top News

Inflation, Consumer Fears Fuel Stock Selloff -- WSJ

28 Mar 2025, 21:49 UTC

Top News

FCC Investigates Disney for DEI Practices, Chair Says -- 2nd Update

28 Mar 2025, 21:28 UTC

Top News

Stocks Fall on Tariff, Consumer Sentiment Fears -- WSJ

28 Mar 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28 Mar 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28 Mar 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28 Mar 2025, 20:40 UTC

Top News

OpenAI's Latest Funding Round Comes With a $20 Billion Catch -- WSJ

28 Mar 2025, 20:36 UTC

Top News

Consumers' Mood Sours in March With Gloomier Economic Outlook -- 4th Update

Peer Comparison

Price change

Camurus AB Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.